title: Bayer challenges India's first compulsory licence for generic version of cancer drug.
authors.forename: Sophie
authors.initials: S
authors.lastname: Arie
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics; D001557:Benzenesulfonates / Q000191:economics; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D016568:Drugs, Generic / Q000191:economics; D006801:Humans; D007194:India; D007880:Legislation, Drug; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000191:economics; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D016568:Drugs, Generic; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib